Conference Contributions 2019
I. Blanchard, T. Armstrong, G. Denys, Y. Ying, M. Kresken, J. Carpenter, V. Sauvonnet, G. Zambardi. Résultats d’essais cliniques multicentriques du nouvel ETEST® Eravacycline sur E. coli, K. pneumoniae et Enterococcus spp. 39e Réunion Interdisziplinaire de Chemiothérapie Anti-Infectieuse (RICAI), Paris, December 16-17, 2019: P-013.
H. Seifert, D. Stefanik , C. Müller, M. Kresken, P. G Higgins, A. Miller The susceptibility of global isolates of Acinetobacter baumannii to ETX2514SUL and comparators. 29th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 13-16, 2019, P1186
M. Kresken, P. G Higgins, D. Stefanik , J. Wille, B. Körber-Irrgang, H. Seifert The evolution of carbapenem resistance determinants and major epidemiological lineages among carbapenem-resistant Acinetobacter baumannii isolates in Germany, 2010 -2016. 29th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 13-16, 2019, P0922
M. Kresken, Y. Pfeifer, J. Bender, B. Körber-Irrgang, G. Werner Extended-spectrum-beta-lactamase (ESBL)-producing strains among clinical isolates of Escherichia coli and Klebsiella pneumoniae from hospitalized patients in Germany, 2010 -2016. 29th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 13-16, 2019, P1209
M. Kresken, Y. Pfeifer, J. Bender, B. Körber-Irrgang, G. Werner Dissemination of extended-spectrum beta-lactamase genes and resistance to oral antibiotics among Escherichia coli urine isolates from outpatient departments in Germany, 2010 -2016. 29th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 13-16, 2019, P1619
M. Kresken, E. Berwian, S. Wernicke, A. Frank, G. Anlauf In vitro activity of cefiderocol against Gram-negative pathogens circulating in Germany 29th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 13-16, 2019, P1859
M. Kresken, F.Layer, B. Körber-Irrgang, G. Werner Prevalence, antibiotic resistance patterns and spa types of MRSA from hospitalised patients in Germany, 2010-2016. 29th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 13-16, 2019, P2699
Conference Contributions 2018
M. Kresken, S. Wernicke, P. Baumann. Polymyxin susceptibility testing with the VITEK® 2 in comparison to the broth microdilution method. Annual Meeting of DGHM, Göttingen, Germany, February 25-27, 2019: 49/DKMV.
M. Kresken, B. Körber-Irrgang, Arbeitsgemeinschaft Empfindlichkeitsprüfungen und Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. Ergebnisse der PEG Resistenzstudie 2016 - Resistenzsituation im stationären Versorgungsbereich. 26. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Wien, 04. - 06. Oktober 2018: Poster Nr. 5.
Poster
M. Kresken, B. Körber-Irrgang, Arbeitsgemeinschaft Empfindlichkeitsprüfungen und Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. Ergebnisse der PEG Resistenzstudie 2016 – Resistenzsituation bei Escherichia coli Urinisolaten gegenüber oral applizierbaren Antibiotika im ambulanten Versorgungsbereich. 26. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Wien, 04. - 06. Oktober 2018: Poster Nr. 6.
Michael Kresken, Barbara Körber-Irrgang, Gunnar Hischebeth, Achim Hoerauf, Nicole von Allmen, Michael Hogardt, Thomas A. Wichelhaus, Niels Pfennigwerth, Sören G. Gatermann. Occurrence of carbapenemase-producing strains among Enterobacterales urine isolates in three geographic areas in Germany. 28th European Congress of Clinical Microbiology and Infectious Diseases, Madrid, Spain, April 21-24, 2018: P1072.
Michael Kresken, Barbara Körber-Irrgang, Miriam Korte-Berwanger, Niels Pfennigwerth, Sören G. Gatermann. Dissemination of carbapenem-resistant, carbapenemase non-producing and carbapenemase-producing Pseudomonas aeruginosa in Germany. 28th European Congress of Clinical Microbiology and Infectious Diseases, Madrid, Spain, April 21-24, 2018: O0124.
Conference Contributions 2017
Kresken M, Körber-Irrgang B. In vitro pharmacodynamics of ceftobiprole against Staphylococcus aureus at concentrations corresponding to free drug levels achieved in human serum. 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 22-25, 2017: P1201.
Kresken M, Körber-Irrgang B, Seifert H, and German Ceftolozan/Tazobactam Study Group. In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates non-susceptible to ceftazidime or meropenem. 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 22-25, 2017: P1235.
Kresken M, Körber-Irrgang B, and Working Party "Antimicrobial Resistance" of the Paul-Ehrlich-Society for Chemotherapy. In vitro activity of mecillinam against urine isolates of Echerichia coli from outpatient departments in Germany. 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 22-25, 2017: EV0561.
Conference Contributions 2016
Kresken M, Körber-Irrgang B, Wallmann J, Kaspar H. GERMAP: Verbreitung von ESBL-bildenden und Chinolon-resistenten Escherichia-coli-Erregerisolaten in der Human- und Veterinärmedizin. 25. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Rostock, 06. - 08. Oktober 2016: Poster Nr. 26.
Körber-Irrgang B, Pfeifer Y, Werner G, Kresken M. In vitro Aktivität von Cefoxitin gegenüber ESBL-produzierenden Escherichia-coli- und Klebsiella-pneumoniae-Isolaten aus dem Hospitalbereich. 25. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Rostock, 06. - 08. Oktober 2016: Poster Nr. 25.
Körber-Irrgang B, Kresken M, Kniehl E, Becker A, Arbeitsgemeinschaft Empfindlichkeitsprüfungen und Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. Epidemiologie und Antibiotika-Empfindlichkeit multiresistenter Gram-negativer (MRGN) Blutkulturisolate in Deutschland - Ergebnisse der Blutkulturstudie im Rahmen der PEG-Resistenzstudie 2013/14. 25. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Rostock, 06. - 08. Oktober 2016: Poster Nr. 12.
Kresken M, Olzowy B, Havel M, Hafner D, Körber-Irrgang B, Arbeitsgemeinschaft Empfindlichkeitsprüfungen und Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. Antibiotika-Empfindlichkeit bakterieller Erreger von Patienten mit HNO-Infektionen in der ambulanten Versorgung - Ergebnisse der PEG-Resistenzstudie 2013 und deren klinische Bedeutung. 25. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Rostock, 06. - 08. Oktober 2016: Poster Nr. 11.
Körber-Irrgang B, Pfeifer Y, Werner G, Kresken M, Arbeitsgemeinschaft Empfindlichkeitsprüfungen und Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. ESBL-Bildung und Fluorchinolon-Resistenz bei Escherichia-coli- und Klebsiella-pneumoniae-Isolaten aus dem Hospitalbereich. 25. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Rostock, 06. - 08. Oktober 2016: Poster Nr. 10.
Kresken M, Körber-Irrgang B, Hafner D für die Arbeitsgemeinschaft Empfindlichkeitsprüfungen & Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie. Verbreitung von multiresistenten Escherichia-coli-Urinisolaten in der ambulanten Patientenversorgung und In-vitro-Aktivität von Nitroxolin: Ergebnisse der PEG-Resistenzstudie 2013. 13. KIT, Würzburg, 15. - 18. Juni 2016: P-117.
Körber-Irrgang B, von Müller L, Westenberger J, Hafner D, Herrmann M, Kresken M, and Working Party "Antimicrobial Resistance" of the Paul-Ehrlich-Society for Chemotherapy. In vitro activity of fidaxomicin and comparators against Clostridium difficile isolates obtained from community and hospitalized patients: results of the PEG study. 13. KIT, Würzburg, 15. - 18. Juni 2016: eP-009.
Poster
Kresken M, Körber-Irrgang B, Seifert H, and German Ceftolozan/Tazobactam Study Group. In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany. 13. KIT, Würzburg, 15. - 18. Juni 2016: eP-011.
Kresken M, Körber-Irrgang B, Hafner D, and Working Party "Antimicrobial Resistance" of the Paul-Ehrlich-Society for Chemotherapy. Multidrug resistance to oral antibiotics in Escherichia coli urine isolates from outpatients in Germany and in vitro activity of nitroxoline: results of the PEG 2013 study. 26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 9-12, 2016: P0077.
Kresken M, Körber-Irrgang B, Hafner D, Kaase M, Pfeifer Y, Layer F, Klare I, Werner G, Seifert H, and Working Party "Antimicrobial Resistance" of the Paul-Ehrlich-Society for Chemotherapy. Prevalence of multidrug resistance among bacterial pathogens obtained from patients in hospitals and the role of tigecycline: results of the PEG 2013 study. 26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 9-12, 2016: P0326.
Körber-Irrgang B, von Müller M, Westenberger J, Hafner D, Herrmann M, Kresken M and Working Party "Antimicrobial Resistance" of the Paul-Ehrlich-Society for Chemotherapy. Comparative susceptibilities of Clostridium difficile isolates to fidaxomicin obtained from community and hospitalized patients: results of the PEG 2013 study. 26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 9-12, 2016: P0615.
Poster
Kresken M, Körber-Irrgang B, Seifert H, and German Ceftolozan/Tazobactam Study Group. In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany. 26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 9-12, 2016: P1314.
Conference Contributions 2015
von Müller L, Herrmann M, Nimmesgern A, Körber-Irrgang B, Kresken M. Resistance profiling and ribotyping of Clostridium difficile isolates in Germany: Results of the PEG study 2013/2014. Annual Meeting of DGHM, Münster, Deutschland, September 27-30 2015: 074/HYP.
Kresken M, Körber-Irrgang B, Hafner D. Susceptibility to ceftobiprole in blood and respiratory isolates collected from hospitalized patients prior to the introduction of this Group 5 cephalosporin: results of the PEG study. Annual Meeting of DGHM, Münster, Deutschland, September 27-30 2015: 184/PRP.
Kresken M, Körber-Irrgang B, Hafner D. Susceptibility to multidrug-resistant pathogens from German hospitals to fosfomycin, 2013: results of the PEG study. Annual Meeting of DGHM, Münster, Deutschland, September 27-30 2015: 188/PRP.
Kresken M, Körber-Irrgang B, Hafner D. Occurrence of multidrug-resistant isolates (3MRGN, 4MRGN) among Gram-negative rods obtained from patients in German hospitals, 1995-2013: results of the PEG study. Annual Meeting of DGHM, Münster, Deutschland, September 27-30 2015: 189/PRP.
Kresken M, Körber-Irrgang B, Hafner D. Occurrence of multidrug-resistant isolates among Gram-positive pathogens obtained from patients in German hospitals, 1995-2013: results of the PEG study. Annual Meeting of DGHM, Münster, Deutschland, September 27-30 2015: 195/PRP.
Kresken M, Körber-Irrgang B, Batista N, Besard V, Garcia-Castillo M, Cantón R, Pascual A, Kalka-Moll W, Schwarz R, Van Meensel B, Wisplinghoff H, Seifert H. Susceptibility of Gram-negative pathogens isolated from patients with community-acquired urinary tract infections in three European Countries. 25th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 25-28, 2015: P0800.
Kresken M, Körber-Irrgang B, Hafner D. In vitro activity of ceftobiprole against clinical isolates collected from blood and respiratory specimen of hospitalized patients: results of the PEG study. 25th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 25-28, 2015: P0831.
Conference Contributions 2014
Körber-Irrgang B, Kresken M. Empfindlichkeit von Gram-negativen und Gram-positiven Harnwegserregern gegenüber Nitroxolin und Nitrofurantoin. 24. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Weimar, 16. - 18. Oktober 2014: Poster Nr. 19.
Poster
Körber-Irrgang B, Kresken M für die Studiengruppe. Resistenzentwicklung von Streptococcus pneumoniae Isolaten gegenüber Doxycyclin, Erythromycin und Penicillin G in Deutschland, 2001-2010. 24. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Weimar, 16. - 18. Oktober 2014: Poster Nr. 11.
Kresken M, Gatermann S. Aktivitäten des Deutschen Nationalen Antibiotika-Sensitivitätstestkomitee (NAK), 2012-2014. 24. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Weimar, 16. - 18. Oktober 2014: Poster Nr. 6.
Kresken M, Wallmann J, Kaspar H, Kern W.V. GERMAP - eine Intitiative von BVL, PEG und Infektiologie Freiburg. 24. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Weimar, 16. - 18. Oktober 2014: Poster Nr. 5.
Poster
Körber-Irrgang B, Pfeifer Y, Wresch R, Kresken M. Occurrence of CTX-M-15 producing Escherichia coli belonging to clonal Group O25B:H4-ST131 in Germany, 2010. 66th DGHM, Dresden, Deutschland, Oktober 5-8, 2014: PRP54.
Körber-Irrgang B, Kresken M. Susceptibility of non Escherichia coli uropathogens to nitroxoline and the in vitro pH-activity relationship. 66th DGHM, Dresden, Deutschland, Oktober 5-8, 2014: PRP53.
Kresken M, Körber-Irrgang B. In vitro activity of ceftaroline against Staphyloccoccus aureus using concentrations achieved in humans determined by time-kill methodology. 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, May 10-13, 2014: eP179.
Kresken M, Körber-Irrgang B. In vitro activity of nitroxoline against uropathogens other than Escherichia coli and impact of pH. 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, May 10-13, 2014: P0243.
Körber-Irrgang B, Pfeifer Y, Wresch R and Kresken M. Strains belonging to clonal Group O25B:H4-ST131 are widely disseminated among CTX-M-15 producing Escherichia coli recovered from in- and outpatients in Germany, 2010. 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, May 10-13, 2014: P1151.
Poster
Kresken M, Körber-Irrgang B. Lack of resistance to nitroxoline in Escherichia coli Urine isolates from outpatients. 12. KIT, Köln, 25. - 28. Juni 2014: Poster Nr. 007.
Poster
Kresken M, Körber-Irrgang B. Feasibility of the disc Diffusion methodology and the M.I.C. Evaluator for susceptibility testing of ceftaroline against Staphylococcus aureus and ESBL-negative Enterobacteriaceae. Bad Honnef-Symposium, Königswinter, 13. - 14. April, 2014: Poster Nr. 2.
Conference Contributions 2013
Körber-Irrgang B, Schedletzky H, Kaase M, Kresken M. The Micronaut-S beta-lactamase VI test is a useful tool for phenotypic carbapenemase detection. Annual Meeting of DGHM, Rostock, Deutschland, September 22-25, 2013: DVP10.
Poster
Körber-Irrgang B, Kresken M. Is nitroxoline an option for the treatment of uncomplicated urinary tract infections? Results of a German multicentre study on its in vitro activity against Escherichia coli urine isolates. Annual Meeting of DGHM, Rostock, Deutschland, September 22-25, 2013: FTP09.
Poster
Körber-Irrgang B, Kresken M on behalf of the Working Party Antimicrobial Resistance of the Paul Ehrlich Society of Chemotherapy. Susceptibility of multidrug resistant organisms to tigecycline: results of the resistance surveillance study conducted by the Paul Ehrlich Society for Chemotherapy, 2010. Annual Meeting of DGHM, Rostock, Deutschland, September 22-25, 2013: NIP05.
Poster
Körber-Irrgang B, Kresken M. Evaluation of ceftaroline susceptibility in Gram-positive and Gram-negative pathogens from hospitalised skin infected patients: results of a surveillance study prior to its clinical use in Germany. Annual Meeting of DGHM, Rostock, Deutschland, September 22-25, 2013: NIP06.
Poster
Kresken M, Körber-Irrgang B, Lass-Flörl C, Groll AH on behalf of the Working Party Antimicrobial Resistance of the Paul Ehrlich Society of Chemotherapy. Epidemiology of Candida species from sterile specimens in Germany and susceptibility to antifungal agents in vitro using the EUCAST method. 23th European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, April 27-30, 2013: P985.
Körber-Irrgang B and Kresken M on behalf of the Working Party Antimicrobial Resistance of the Paul Ehrlich Society of Chemotherapy. In vitro antibacterial activity of tigecycline against 434 multidrug resistant pathogens in Germany and a central European area, 2010. 23th European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, April 27-30, 2013: P1522.
Kresken M, Körber-Irrgang B and Hafner D on behalf of the Working Party Antimicrobial Resistance of the Paul Ehrlich Society of Chemotherapy. Susceptibility of Gram-negative pathogens from hospitalized patients to colistin and fosfomycin in Germany 2010. 23th European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, April 27-30, 2013: P1531.
Körber-Irrgang B, Schedletzky H, Kaase M and Kresken M. Phenotypic detection of carbapenemase-producing Gram-negative bacteria by using the MICRONAUT-S system for antimicrobial susceptibility testing. 23th European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, April 27-30, 2013: P1557.
Kresken M and Körber-Irrgang B on behalf of the German Ceftaroline Study Group. In vitro activity of ceftaroline against Gram-positive and Gram-negative pathogens obtained from hospitalised skin infected patients in Germany, 2011-2012. 23th European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, April 27-30, 2013: P1618.
Körber-Irrgang B and Kresken M. Frontline identification of bacterial isolates using the MALDI Biotyper-system during a resistance surveilllance study in a central European area, 2010. 23th European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, April 27-30, 2013: P1718.
Conference Contributions 2012
Kresken M, Körber-Irrgang B. Resistenzhäufigkeit gegen Fosfomycin bei Escherichia-coli-Urinisolaten von Patientinnen aus dem ambulanten Versorgungsbereich - Ergebnisse der PEG Resistenzstudie aus dem Jahr 2010. 59. Jahreskongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe e.V., München, 9. - 13. Oktober 2012: Poster Nr: PO-Geb 07.02.
Gatermann S, Kresken M. Was ist NAK? 23. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Dresden, 11. - 13. Oktober 2012: Poster Nr. 5.
Kresken M, Körber-Irrgang B, Hafner D, Kaase M für die Arbeitsgemeinschaft Empfindlichkeitsprüfung & Resistenz. Antibiotikaempfindlichkeit Carbapenem-nicht sensibler Enterobacteriaceae. 23. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Dresden, 11. - 13. Oktober 2012: Poster Nr. 6.
Körber-Irrgang B, Klare I, Layer F, Werner G, Kresken M für die Arbeitsgemeinschaft Empfindlichkeitsprüfung & Resistenz. Verbreitung nosokomialer Vancomycin-resistenter Enterokokken (VRE) in Deutschland und im mitteleuropäischen Raum. 23. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Dresden, 11. - 13. Oktober 2012: Poster Nr. 7.
Poster
Körber-Irrgang B, Layer F, Klare I, Werner G, Kresken M für die Arbeitsgemeinschaft Empfindlichkeitsprüfung & Resistenz. Verbreitung von MRSA-Klonen bei hospitalisierten Patienten in Deutschland und im mitteleuropäischen Raum. 23. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Dresden, 11. - 13. Oktober 2012: Poster Nr. 8.
Kresken M, Körber-Irrgang B, Ceftarolin-Studiengruppe. In-vitro-Aktivität von Ceftarolin gegen Gram-positive und Gram-negative Erreger von hospitalisierten Patienten mit komplizierten Haut/Weichgewebeinfektionen: Interimsanalyse der Ergebnisse einer multizentrischen Studie in Deutschland. 23. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Dresden, 11. - 13. Oktober 2012: Poster Nr. 18.
Poster
Kresken M, Körber-Irrgang B. Antibiotika-Empfindlichkeit bei Pseudomonas-aeruginosa-Isolaten von Non-CF-Patienten aus dem ambulanten Versorgungsbereich - Ergebnisse der PEG Resistenzstudie 2010. 11. KIT, Köln, 25. - 28. April 2012: Poster Nr. 103.
Poster
Körber-Irrgang B, Kresken M. Frontline-Identifizierung mit dem MALDI Biotyper - Erfahrungen aus der PEG Resistenzstudie. 11. KIT, Köln, 25. - 28. April 2012: Poster Nr. 110.
Kresken M, Körber-Irrgang B on behalf of the Working Party Antimicrobial Resistance of the Paul Ehrlich Society of Chemotherapy. Occurrance of resistance to fosfomycin in urine isolates of E.coli collected from outpatients in Germany, 2010. 22th European Congress of Clinical Microbiology and Infectious Diseases, London, UK, March 31 - April 3, 2012: P1533. Clin Microbiol Infect 2012;18(issue s3):S412.
Körber-Irrgang B, Zander E, Ritzenhoff A, Bauernfeind A, Schneider I, Kresken M. Emergence and genetic environment of CTX-M enzymes produced by clinical Escherichia coli isolates in Germany, 2005-2009. 22th European Congress of Clinical Microbiology and Infectious Diseases, London, UK, March 31 - April 3, 2012: P1665. Clin Microbiol Infect 2012;18(issue s3):S460.
Conference Contributions 2011
Kresken M, Hafner D. Trends in multidrug resistance among Escherichia coli and klebsiellae in Germany. 63rd Annual Meeting of DGHM, Essen, Deutschland, September 25-28, 2011: ERP01. International Journal of Medical Microbiology; 301S1:S16.
Kresken M, Hafner D. No evidence of an overall increase in vancomycin MICs of German MRSA isolates between 2001 and 2009. 63rd Annual Meeting of DGHM, Essen, Deutschland, September 25-28, 2011: ERP02. International Journal of Medical Microbiology; 301S1:S17.
Kresken M, Becker K, Seifert H, Körber-Irrgang B, von Eiff C, Löschmann PA. Susceptibility of major bacterial pathogens to tigecycline in Germany, 2004-2009. 63rd Annual Meeting of DGHM, Essen, Deutschland, September 25-28, 2011: ERP03. International Journal of Medical Microbiology; 301S1:S17.
Kresken M, Körber-Irrgang B, Decker-Burgard S, Hafner D. Pharmacodynamics of three carbapenems considering the current susceptibility patterns of drug-resistant Gram-negative bacteria in Germany. 63rd Annual Meeting of DGHM, Essen, Deutschland, September 25-28, 2011: ERP04. International Journal of Medical Microbiology; 301S1:S18.
Kresken M, Körber-Irrgang B. Antimicrobial susceptibility of ocular isolates in Germany, 2004-2009. 63rd Annual Meeting of DGHM, Essen, Deutschland, September 25-28, 2011: ERP07. International Journal of Medical Microbiology; 301S1:S18-9.
Körber-Irrgang B, Bauernfeind A, Schneider I, Kresken M. Prevalence of CTX-M producing strains among Escherichia coli isolates from hospitalized patients in Germany, 2005-2009. 63rd Annual Meeting of DGHM, Essen, Deutschland, September 25-28, 2011: ERP12. International Journal of Medical Microbiology; 301S1:S20.
Poster
Abstract
Kresken M, Hafner D. Susceptibility of Gram-negative pathogens to colistin and comparators in Germany. 63rd Annual Meeting of DGHM, Essen, Deutschland, September 25-28, 2011: ERV04. International Journal of Medical Microbiology; 301S1:S22.
Abstract
Kresken M, Körber-Irrgang B on behalf of the Study Group. Feasibility of the Etest for susceptibility testing of doripenem against Gram-negative and Gram-positive bacteria using EUCAST breakpoints. 21th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, May 7-10, 2011: P754. Clin Microbiol Infect 2011;17(issue s4):S174.
Kresken M, Körber-Irrgang B, Decker-Burgard S, Hafner D. Pharmacodynamics of three carbapenems against drug-resistant Gram-negative pathogens isolated from hospitalised patients in Germany using Monte Carlo Simulation. 21th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, May 7-10, 2011: P808. Clin Microbiol Infect 2011;17(issue s4):S192-3.
Poster
Abstract
Kresken M, Körber-Irrgang B on behalf of the German Ophthalmologic Study Group. Susceptibility to antibacterial agents in Germany amongst ocular isolates, 2004-2009: results of two laboratory surveillance studies. 21th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, May 7-10, 2011: P1097. Clin Microbiol Infect 2011;17(issue s4):S288.
Poster
Abstract
Kresken M, Becker K, Seifert H, Körber-Irrgang B, von Eiff C, Löschmann PA on behalf of the German Tigecycline Study Group. Tigecycline susceptibility trends in Germany among Gram-positive and Gram-negative pathogens recovered from wounds, the peritoneal cavity and blood. 21th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, May 7-10, 2011: P1123. Clin Microbiol Infect 2011;17(issue s4):S297.
Conference Contributions 2010
Kresken M, Körber-Irrgang B for the Study Group. In vitro activity of carbapenems against German isolates of Pseudomonas aeruginosa and the Acinetobacter baumannii group and comparison of the Etest and broth microdilution method for doripenem susceptibility testing. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, USA, September 12-15, 2010: Abstract #D-742.
Kresken M, Becker K, Seifert H, Körber-Irrgang B, Leitner E, von Eiff C for the Study Group. Tigecycline in vitro activity against multi-drug resistant pathogens from Germany. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, USA, September 12-15, 2010: Abstract #E-1599.
Körber-Irrgang B, Lukas AM, Bauernfeind A, Schneider I, Kresken M. Shift towards CTX-M-15 as the predominant type of CTX-M Extended-Spectrum Beta-Lactamase produced by Escherichia coli isolates from hospitalized patients in Germany between 2005 and 2007. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, USA, September 12-15, 2010: Abstract #C2-678.
Kresken M, Hafner D on behalf of the Working Party Antimicrobial Resistence of the Paul Ehrlich Society of Chemotherapy. Susceptibility of Gram-negative pathogens to colistin and comparators in Germany, 2007. 20th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 10-13, 2010: P1638. Clin Microbiol Infect 2010;16(issue s2):S479.
Poster
Abstract
Kresken M, Hafner D on behalf of the Working Party Antimicrobial Resistence of the Paul Ehrlich Society of Chemotherapy. Trends in multidrug resistance among Escherichia coli and klebsiellae in Germany, 1995-2007. 20th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 10-13, 2010: P1312. Clin Microbiol Infect 2010;16(issue s2):S370-1.
Körber-Irrgang B, Röhrig A, Pletz M, Kresken M. Prevalence of first-step parC mutans with amino acid alterations at resistance hot spots S79 and D83 among Streptococcus pneumoniae isolates in Germany. 20th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 10-13, 2010: P993. Clin Microbiol Infect 2010;16(issue s2):S269-70.
Körber-Irrgang B, Kresken M. In-vitro activity of daptomycin combined with other antimicrobial agents against Gram-negative bacteria. 20th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 10-13, 2010: P646. Clin Microbiol Infect 2010;16(issue s2):S156-7.